192 related articles for article (PubMed ID: 24325392)
1. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir.
De Schutter T; Andrei G; Topalis D; Duraffour S; Mitera T; van den Oord J; Matthys P; Snoeck R
Mol Cancer; 2013 Dec; 12():158. PubMed ID: 24325392
[TBL] [Abstract][Full Text] [Related]
2. Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1.
Topalis D; Nogueira TC; De Schutter T; El Amri C; Krečmerová M; Naesens L; Balzarini J; Andrei G; Snoeck R
Oncotarget; 2016 Mar; 7(9):10386-401. PubMed ID: 26824416
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro.
Hostetler KY; Rought S; Aldern KA; Trahan J; Beadle JR; Corbeil J
Mol Cancer Ther; 2006 Jan; 5(1):156-9. PubMed ID: 16432174
[TBL] [Abstract][Full Text] [Related]
4. Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.
Mertens B; Nogueira T; Stranska R; Naesens L; Andrei G; Snoeck R
Oncotarget; 2016 Jul; 7(30):47302-47318. PubMed ID: 27331622
[TBL] [Abstract][Full Text] [Related]
5. The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.
Deberne M; Levy A; Mondini M; Dessen P; Vivet S; Supiramaniam A; Vozenin MC; Deutsch E
Anticancer Drugs; 2013 Jul; 24(6):599-608. PubMed ID: 23698251
[TBL] [Abstract][Full Text] [Related]
6. Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice.
De Schutter T; Andrei G; Topalis D; Duraffour S; Mitera T; Naesens L; van den Oord J; Matthys P; Snoeck R
Cancer Lett; 2013 Feb; 329(2):137-45. PubMed ID: 23142293
[TBL] [Abstract][Full Text] [Related]
7. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice.
Yang Y; Zhao X; Chen W; Gao Z; Liu A; Guo J; Yan Z; Dou Y; Wang H; Li Y
Oncol Res; 2010; 18(11-12):519-27. PubMed ID: 20939427
[TBL] [Abstract][Full Text] [Related]
8. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.
De Schutter T; Andrei G; Topalis D; Naesens L; Snoeck R
BMC Med Genomics; 2013 May; 6():18. PubMed ID: 23702334
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
10. Cidofovir: a novel antitumor agent for glioblastoma.
Hadaczek P; Ozawa T; Soroceanu L; Yoshida Y; Matlaf L; Singer E; Fiallos E; James CD; Cobbs CS
Clin Cancer Res; 2013 Dec; 19(23):6473-83. PubMed ID: 24170543
[TBL] [Abstract][Full Text] [Related]
11. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir.
Catalani S; Palma F; Battistelli S; Nuvoli B; Galati R; Benedetti S
Toxicol In Vitro; 2017 Jun; 41():49-55. PubMed ID: 28223140
[TBL] [Abstract][Full Text] [Related]
12. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Abdulkarim B; Sabri S; Deutsch E; Chagraoui H; Maggiorella L; Thierry J; Eschwege F; Vainchenker W; Chouaïb S; Bourhis J
Oncogene; 2002 Apr; 21(15):2334-46. PubMed ID: 11948417
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):533-9. PubMed ID: 10338156
[TBL] [Abstract][Full Text] [Related]
14. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.
Liekens S; Noppen S; Gijsbers S; Sienaert R; Ronca R; Tobia C; Presta M
Oncotarget; 2015 Mar; 6(7):4633-48. PubMed ID: 25609197
[TBL] [Abstract][Full Text] [Related]
15. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of cidofovir resistant vaccinia viruses.
Becker MN; Obraztsova M; Kern ER; Quenelle DC; Keith KA; Prichard MN; Luo M; Moyer RW
Virol J; 2008 May; 5():58. PubMed ID: 18479513
[TBL] [Abstract][Full Text] [Related]
17. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir.
Kinchington PR; Araullo-Cruz T; Vergnes JP; Yates K; Gordon YJ
Antiviral Res; 2002 Oct; 56(1):73-84. PubMed ID: 12323401
[TBL] [Abstract][Full Text] [Related]
18. Cidofovir induces an increase in levels of low-risk and high-risk HPV E6.
Donne AJ; Hampson L; He XT; Rothera MP; Homer JJ; Hampson IN
Head Neck; 2009 Jul; 31(7):893-901. PubMed ID: 19283851
[TBL] [Abstract][Full Text] [Related]
19. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.
Williams-Aziz SL; Hartline CB; Harden EA; Daily SL; Prichard MN; Kushner NL; Beadle JR; Wan WB; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2005 Sep; 49(9):3724-33. PubMed ID: 16127046
[TBL] [Abstract][Full Text] [Related]
20. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
